CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 4,819 enrolled
Drug / intervention
Spiolto® Respimat®drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03663569
NCT03663569N/ACompleted
CompareCT.gov

Changes in Clinical Control of COPD Patients Measured by the Clinical COPD Questionnaire During Therapy With Spiolto®Respimat® in Routine Clinical Practice

Boehringer Ingelheim·observational·Posted Sep 10, 2018·Updated Jan 7, 2025

In Brief

An observational study evaluating Spiolto® Respimat® for Pulmonary Disease, Chronic Obstructive. Completed, enrolled 4,819 participants across 388 sites in 11 countries.

Detailed Summary

Open-label observational study which includes COPD patients that are receiving treatment with Spiolto® Respimat® for approximately 6 weeks, which is the average time between two medical consultations.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Disease, Chronic Obstructive
CountriesBulgaria, Czechia, Hungary, Israel, Lithuania, Poland, Romania, Russia, Slovenia, Switzerland, Ukraine
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedSep 10, 2018
Enrollment StartAug 15, 2018
Primary CompletionOct 4, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 7.8 years ago

Interventions

Spiolto® Respimat®drug

Drug